Paragon 28, Inc. (NYSE: FNA) saw its stock price surge 5.1% in Friday's intraday trading session, following the release of its impressive third-quarter results and analysts' positive outlook for the company.
The medical device company reported better-than-expected revenue of $62 million, beating analysts' forecasts by 2.9%. Additionally, Paragon 28's earnings loss of $0.15 per share was narrower than anticipated, outperforming estimates by 3.8%.
Analysts have responded favorably to the company's performance, with the consensus price target of $14.40 implying further upside potential. Notably, some analysts have set bullish price targets as high as $20 per share, indicating confidence in Paragon 28's growth prospects.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.